Compare NE & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NE | CELC |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | United States |
| Employees | 4500 | N/A |
| Industry | Other Specialty Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.0B |
| IPO Year | N/A | 2017 |
| Metric | NE | CELC |
|---|---|---|
| Price | $46.77 | $89.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $46.00 | ★ $112.56 |
| AVG Volume (30 Days) | ★ 1.2M | 1.2M |
| Earning Date | 04-26-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.18 | $720.19 |
| P/E Ratio | $32.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.24 | $11.54 |
| 52 Week High | $54.98 | $151.02 |
| Indicator | NE | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 25.86 |
| Support Level | $45.44 | $45.64 |
| Resistance Level | $47.44 | $115.19 |
| Average True Range (ATR) | 1.59 | 9.51 |
| MACD | -0.73 | -5.33 |
| Stochastic Oscillator | 8.06 | 8.98 |
Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and on deploying its drilling rigs in oil and gas basins around the world. The mobile offshore drilling units comprising the offshore rig fleet operate in international markets for contract drilling services and are often redeployed to different regions due to changing customer demand, which consists mainly of large, integrated, independent, and government-owned or controlled oil and gas companies throughout the world.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.